Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer
about
Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesionsBiomarkers of HIV-associated Cancer.The clinical performance of APTIMA human papillomavirus and Hybrid Capture 2 assays in the triage of lesser abnormal cervical cytologiesHuman papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic reviewType-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia.Acceptability and Accuracy of Cervical Cancer Screening Using a Self-Collected Tampon for HPV Messenger-RNA Testing among HIV-Infected Women in South AfricaHead-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.Human Papillomavirus Assays and Cytology in Primary Cervical Screening of Women Aged 30 Years and Above.Detection of Human Papillomavirus Infections at the Single-Cell Level.Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening roundsComparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA.High-risk human papillomavirus (hrHPV) E6/E7 mRNA testing by PreTect HPV-Proofer for detection of cervical high-grade intraepithelial neoplasia and cancer among hrHPV DNA-positive women with normal cytologyLimitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening.Human Papillomavirus Laboratory Testing: the Changing ParadigmHPV-based Tests for Cervical Cancer Screening and Management of Cervical Disease.Retrieval of HPV oncogenes E6 and E7 mRNA from cervical specimens using a manual open technology protocolStability of cervical specimens in SurePath medium for human papillomavirus testing with the Roche cobas 4800 assay.The Aptima HPV assay fulfills the cross-sectional clinical and reproducibility criteria of international guidelines for human papillomavirus test requirements for cervical screeningDisagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening.Comparison of commercial hybridization and automated transcription-mediated amplification modalities for detection of high-risk human papillomavirus nucleic acid.Effect of preanalytical processing of ThinPrep specimens on detection of high-risk human papillomavirus by the Aptima HPV assay.Testing for human papillomavirus in cervical cancer screening: a review of indications and methodology.Human papillomavirus testing and genotyping in cervical screening.The APTIMA HPV assay versus the Hybrid Capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy.Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.Understanding HPV tests and their appropriate applications.FHACT: the FISH-based HPV-associated cancer test that detects nonrandom gain at four genomic loci as biomarkers of disease progression.Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.Molecular approaches for HPV genotyping and HPV-DNA physical status.Current and Emerging Molecular Tests for Human Papillomavirus-Related Neoplasia in the Genomic Era.Referral population studies underestimate differences between human papillomavirus assays in primary cervical screening.Sensitivity of APTIMA HPV E6/E7 mRNA test in comparison with hybrid capture 2 HPV DNA test for detection of high risk oncogenic human papillomavirus in 396 biopsy confirmed cervical cancers.HPV E6/E7 mRNA versus HPV DNA biomarker in cervical cancer screening of a group of Macedonian women.Prospective evaluation of E6/E7 mRNA detection by the NucliSENS Easy Q HPV assay in a stepwise protocol.Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.Evaluation of p16(INK4a)/Ki-67 dual stain in comparison with an mRNA human papillomavirus test on liquid-based cytology samples with low-grade squamous intraepithelial lesion.Effectiveness of HPV 16 viral load and the E2/E6 ratio for the prediction of cervical cancer risk among Chinese women.E6/E7 proteins are potential markers for the screening and diagnosis of cervical pre-cancerous lesions and cervical cancer in a Chinese population.Stability, integrity, and recovery rate of cellular nucleic acids preserved in a new liquid-based cytology medium.HPV genotype determination and E6/E7 mRNA detection for management of HPV positive women.
P2860
Q24198236-A31FF7A5-1BB7-4E82-A798-80F0EF0CF707Q33856851-622DA74A-D0EB-4D0F-80F8-E24A9A9E4F51Q34330297-EE99F73F-59C6-432E-B0B0-FA3C52373309Q34997580-3CC065BE-A25D-4224-B74D-59F531C4A8E7Q35530550-E71F383E-A430-45C0-95A8-42647DCF5EE9Q35762277-8386EF85-597E-470C-8D07-F0E58EBBBDF8Q35868702-40B04E98-040B-4BDF-B9EE-E38D7C6B7ABBQ35898888-3F38890E-2797-476B-BC61-1A77A2F0392EQ35907151-0E3C0819-E912-4A06-B2FF-F38D3A47A7A7Q36023019-D2E55191-ED03-4810-9418-7F9F21437964Q36118559-316873C9-5F22-4AA4-9CD4-245AF8C562C5Q36118590-52439077-E6B4-4CED-9FCC-8314412D8C51Q36395656-B0267BBF-F53F-478B-B516-4DD069D4BB66Q36675236-EEA08B30-3A42-4B72-9A69-065202211A66Q36856284-0AFC21DF-4BA6-4B21-B25C-B962DF221B6EQ37225996-40B13F05-3072-4F2B-A731-B45F277101C7Q37264271-4E3ADEF7-9130-4C76-9037-1D7412754CBDQ37470374-46800BC1-E564-400E-A672-42914F7E2DF2Q37496183-0E31270F-3F3C-4BAC-929C-42CC8CC38BF9Q37546570-80702F7C-2DA6-4319-8C41-512569D0A75DQ37713738-F414B174-0193-4943-88AD-945430070905Q37896031-F353F090-C92D-43A2-9FF7-968064563C29Q37909359-643AF1D5-EB15-4B47-9329-8FBADECD0A42Q38011639-D20D0A31-4826-42D3-9374-4272848F72BAQ38123772-6FACD2ED-CF7E-4DCC-9211-775FAF141171Q38133612-50F051A4-43C3-497D-ACBE-081D2F1725E7Q38259453-C9F761D9-5333-4CF5-AFF8-25D12B21F778Q39013857-F4F3D09A-D8C1-4F9B-9862-43974FD701A9Q39120200-8FD11578-75E0-4089-9CEE-20BB8AE8BA2BQ39191687-2B89B846-EA3D-4BD3-B0A8-62B6232AE51AQ40043990-486A1D2A-63F3-46B9-948C-A483FECE6B75Q40861259-E1A45A52-AF0A-4F4C-838D-1AF0DACCD851Q41328485-2B768F4E-726C-4DE7-BD0C-3EE7F868EAFAQ42278781-1AABC7F1-27B0-4DE0-8409-B8EBC5BD7633Q43524242-96615E8A-9AA6-4C9C-A9E5-6704863B1182Q44451879-E2B50DDB-0DD2-40D1-8E82-0839D7265CE4Q45903948-0DBAAA12-40F9-4F5A-AF25-BD5D8B8F96EEQ47113153-6C1C77DA-007D-4ACB-99F7-0A2CC72B5C98Q48227578-18C31159-FB35-4BA2-B9A2-C176B6131E60Q54247283-CDC9D410-610E-42B7-BAE5-F575A7234E4B
P2860
Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@ast
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@en
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@nl
type
label
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@ast
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@en
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@nl
prefLabel
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@ast
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@en
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@nl
P2093
P2860
P356
P1476
Aptima HPV E6/E7 mRNA test is ...... cervical precancer and cancer
@en
P2093
Adrian Lear
Christopher Giede
Dan Fontaine
Elias Bartellas
Francois Coutlee
Glen Holloway
James Bentley
Nicholas Escott
Prafull Ghatage
P2860
P304
P356
10.1128/JCM.02147-10
P407
P577
2010-12-08T00:00:00Z